Trifluoperazine, a calmodulin antagonist, inhibits muscle cell fusion by unknown
Trifluoperazine,  a Calmodulin 
Inhibits Muscle Cell  Fusion 
Antagonist, 
DAFNA  BAR-SAGI and  JOAV PRIVES 
Cellular and Developmental Biology Program, and Department of Anatomical Sciences, Health Sciences 
Center, State University of New York at Stony Brook, Stony Brook, New York 11794 
ABSTRACT  We investigated the effect of trifluoperazine  (TFP), a calmodulin antagonist, on the 
fusion of chick skeletal myoblasts in culture.  TFP was found to inhibit myoblast fusion. This 
effect occurs at concentrations that have been reported to inhibit Ca2+-calmodulin in vitro, 
and is  reversed upon  removal of TFP. In addition,  other calmodulin  antagonists, including 
chlorpromazine,  N-(6-aminohexyl)-5-chloro-l-naphthalene-sulfonamide  (W7), and N-(6-ami- 
nohexyl)-l-naphthalene-sulfonamide  (W5), inhibit fusion at doses that correspond closely to 
the antagonistic effects of these drugs on calmodulin. The expression of surface acetylcholine 
receptor,  a characteristic  aspect of muscle differentiation,  is  not  impaired  in  TFP-arrested 
myoblasts. Myoblasts inhibited from fusion by 10 ~M TFP display impaired alignment. In the 
presence of the Ca  2÷ ionophore A23187, the fusion block by 10 ~,M TFP is partially reversed 
and  myoblast alignment  is  restored. The  presence and distribution  of calmodulin  in  both 
prefusional myoblasts and fused muscle cells was established by immunofluorescence.  We 
observed an apparent redistribution  of calmodulin  staining that is temporally correlated with 
the  onset  of  myoblast  fusion.  Our  findings  suggest a possible role  for  calmodulin  in  the 
regulation of myoblast fusion. 
A characteristic event in the differentiation of skeletal muscle 
cells is the fusion of mononucleated myoblasts into multinu- 
cleated myotubes. Studies using cultured muscle cells have 
shown that Ca  2÷ plays an essential role in mediating myoblast 
fusion: reduction in  Ca  2÷ concentration in the culture me- 
dium causes arrest of myoblast fusion, and fusion is rapidly 
renewed upon readdition of Ca  2÷ (8, 38, 39, 48, 49). 
There is now substantial evidence that Ca  2÷ regulation in a 
variety of eukaryotic cells  is mediated by the Ca2÷-binding 
protein calmodulin. Calmodulin has been implicated in the 
mediation of Ca  2÷ regulation of  cyclic nucleotide metabolism, 
protein phosphorylation, microtubule assembly, cell motility, 
and Ca  2÷ flux across cell membranes (for reviews see refer- 
ences 3,  20,  29).  The phenothiazine trifluoperazine (TFPp 
binds to the Ca2÷-activated  form of calmodulin (23, 24) and 
inhibits its interaction with cellular target proteins (2, 24, 25, 
50, 51). Consequently, TFP has been used as a pharmacolog- 
ical  probe to study the participation of Ca2+-calmodulin  in 
Abbreviations used in this paper.  AChR,  acetylcholine  receptor; 
CPZ, chlorpromazine; TFP, trifluoperazine;  W-5, N-(6-aminohexyl)- 
l-naphthalene-sulfonamide;  W-7,  N-(6-aminohexyl)-5-chloro-1- 
naphthalene-sulfonamide. 
the regulation of Ca2+-dependent  cellular events (5,  17,  33, 
36, 37). Recently, TFP and phenothiazines closely related to 
TFP have been shown to interact with Ca2+-binding proteins 
distinct from calmodulin (4, 30, 31). 
In the present study we investigated the effects of TFP on 
the fusion of embryonic chick muscle cells  in  culture. We 
compared these effects with the action of other calmodulin 
inhibitors, as well as with the effects of Ca  2+ depletion. This 
study constitutes an  initial  step  toward elucidation of the 
possible role of Ca2+-binding  proteins in  the  regulation of 
myoblast fusion. 
MATERIALS AND  METHODS 
Materials:  TFP and chlorpromazine  (CPZ) were a  gift of the Smith 
Kline and French Laboratories, Philadelphia, PA. N-(6-aminohexyl)-5-chloro- 
I-naphthalene-sulfonamide  (W-7)  and  N-(6-aminohexyl)-l-naphthalene-sul- 
fonamide (W-5) were purchased  from CAABCO, Inc. (Houston,  TX). These 
drugs were stored dessicated in the dark, and dissolved immediately before use. 
The Ca  2+ ionophore  A23187 was obtained  from Calbiochem-Bchring  Corp., 
San Diego, CA. A 20-mM  stock solution  was prepared  in dimethylsulfoxide 
(DMSO; Fisher Scientific Co., Pittsburgh, PA), diluted to working concentra- 
tion (10 ~,M) in growth medium, and added to cultures at a final concentration 
of 0.5 ~,M A23187 and 0.0025% DMSO. At this concentration  DMSO had no 
effect of myoblast  fusion.  Sheep  anticalmodulin  lgG was purchased  from 
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chased from Miles Laboratories Inc. (Elkhart, IN). EGTA was purchased from 
Fisher Scientific Co.  ~2Sl-a-bungarotoxin (~2SI-Bgt) was purchased  from New 
England Nuclear (Boston, MA). Other reagents were from Sigma Chemical Co. 
(St. Louis, MO). Tissue culture media were purchased from Gibco Laboratories 
(Grand Island, NY). 
Cell Culture:  Primary cultures of skeletal muscle cells were prepared 
from breast of 12-d-old chick embryos as described (35, 38). Cells were plated 
on collagen-coated culture dishes at an initial density of 1.8 x  l06 cells/60-mm 
culture  dish.  Cultures  were grown  in  Dulbecco's  modified  Eagle's medium 
(DME), supplemented with  10% horse serum and 2% chick embryo extract at 
37"C in an atmosphere of 92% air/8% CO2. Cultures were not fed after plating, 
and drugs were added directly to the growth medium. 
Measurement of Cell Fusion:  Cultures were rinsed twice with PBS 
and fixed for 5 rain in methanol.  After fixation, cells were stained with a  10% 
Giemsa  solution  (l:l  methanol/glyeerol)  for 20  rain and rinsed with water. 
Cell fusion was scored by light microscopy at a magnification of 250. Mono- 
nucleated myoblasts were distinguished from fibroblasts on the basis of mor- 
phological differences between these two cell types. Percentage fusion is defined 
as the ratio of the number of nuclei in myotubes to the total number of nuclei 
in both myoblasts and myotubes.  For this purpose,  cells containing  three  or 
more nuclei are considered myotubes. Each value represents the average of at 
least  l0  randomly  selected fields with  a total  number of nuclei  >500.  The 
variations  between counts from different  fields did  not exceed 10%  of the 
average value. Cell protein was determined by the method of Lowry et al. (27). 
Measurement of Acetylcholine Receptor (AChR):  AChR  on 
the surface of intact muscle ceils was measured by the specific binding of t2Sl- 
Bgt as described previously (38). After two washes with DME, cultures were 
incubated with L2SI-Bgt (10 nM) in 1 ml DME containing  1 mg/ml BSA for 1 
h at 37"C. Unbound toxin was removed by five washes with DME and cells 
were suspended in 1 N NaOH containing  1% Triton X-100. Radioactivity was 
determined  by gamma spectroscopy. Nonspeeific binding, established in repli- 
cate cultures  in the presence  of the competitive  ligand decamethonium  (10 
#M), was subtracted, and it accounted for <10% of total labeling. 
Indirect Immunofluorescence:  Cultures were fixed with methanol 
for 10 min at -20"C. Prefixation with 3.7% formaldehyde yielded equivalent 
results. The fixed cells were rinsed with PBS and incubated with sheep anti-rat 
testis calmodulin  (100 t~g/ml in PBS containing  1% BSA) for 45 min at 37"C. 
The cells were then rinsed five times for 10 rain in PBS and incubated  with 
preadsorbed  fluorescein  isothiocyanate  (FITC)  rabbit  anti-sheep  antibodies 
( 1:200 dilution in PBS containing  1% BSA) for 45 min at 37"C. The cells were 
washed five times  with  PBS and once  with  water, and were mounted with 
Aqua-Mount (Lerner Laboratories, New Haven, CT). FITC rabbit anti-sheep 
antibodies were preadsorbed on methanol-fixed muscle cell monolayers. Con- 
trol staining, carried out using second antibody  alone, yielded very low back- 
ground  fluorescence.  Fluorescence  was observed  with  a  Zeiss  fluorescence 
microscope equipped with epi-illumination and with the appropriate fluorescein 
excitation  and emission  filters. Images were photographed  on Kodak  Tri-X 
film (Eastman Kodak Co., Rochester, NY) rated at 1100 ASA. 
RESULTS 
Under the culture conditions used in this study,  myoblasts 
undergo rapid fusion during the second day post-plating (Fig. 
1). Synchronous fusion of aligned, bipolar myoblasts is initi- 
ated at ~24 h after plating and is essentially complete by 54 
h  post-plating.  Addition  of TFP to  cultures,  at  24  h  after 
plating, inhibits subsequent fusion (Fig.  1). As can be seen, 
this effect is dose dependent; inhibition is significant at con- 
centrations as low as 5 #M TFP and is essentially total at 10 
#M TFP. The low concentrations of TFP that are effective in 
eliciting inhibition of myoblast fusion are similar to the TFP 
concentrations reported to inhibit calmodulin activity in vitro 
(IDso =  10 #M; reference 50). 
To establish further whether the TFP inhibition of fusion 
is consistent with the effect of this drug on calmodulin, we 
compared the effect of TFP with that of a related phenothi- 
azine, CPZ, as well as with those of W-5 and W-7, calmodulin 
antagonists that are structurally unrelated to phenothiazines. 
The effects of various concentrations  of CPZ on  myoblast 
fusion  are  shown  in  Fig.  2.  The  percentage  of fusion  is 
decreased by CPZ in a dose-dependent manner, first detecta- 
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FIGURE  1  Effect of TFP on myoblast fusion. Cultures were treated 
with the indicated concentrations of TFP at 24 h postplating and 
percentage fusion was determined as described under Materials 
and Methods. Values shown are the averages of three determina- 
tions. Bars represent the range. 
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FIGURE  2  Effect of increasing concentrations of TFP (O), CPZ (O), 
W-7  (&), and W-5  (1) on myoblast fusion. Cultures were treated 
with  the  drugs  at  24  h  postplating, and  percentage fusion  was 
determined at  30  h  after  drug  addition. Values  shown  are the 
averages of 3 determinations. Bars represent the range. The per- 
centage fusion of untreated control cultures was 80 _ 4%. 
ble at 15 /LM and attaining a maximum at 30/zM.  In com- 
parison, an approximately threefold-lower concentration  of 
TFP is required for achieving an equivalent degree of fusion 
inhibition.  A  similar relationship has been reported for the relative potencies of CPZ and TFP in the inhibition of cal- 
modulin in vitro (50). W-7, a nonphenothiazine inhibitor of 
calmodulin (13,  14), blocks myoblast fusion (Fig.  2). The W- 
7 concentration required for 50% inhibition of fusion is ~75 
pM. A  related sulfonamide derivative,  W-5,  is a less potent 
inhibitor of calmodulin (13). W-5  inhibits muscle  fusion as 
well, but, as shown in Fig.  2, at significantly higher concen- 
trations than W-7. 
To test whether the inhibitorY effect of TFP on myoblast 
fusion is reversible,  TFP was added to cells at 24 h postplating, 
for 30 h. The drug-containing medium was then replaced by 
conditioned medium,  and fusion was monitored during the 
subsequent 48 h. As shown in Fig. 3, the fusion block induced 
by the various concentrations of TFP is reversible.  The extent 
of fusion increases gradually after TFP removal and reaches 
approximately control levels after  48  h.  In comparison, the 
block of fusion was maintained in the presence of TFP (10 
vM) during this interval (Fig.  3). 
The requirement of the process of muscle fusion for extra- 
cellular calcium  (8,  38,  39,  48)  has been  illustrated by the 
effectiveness of the calcium chelator EGTA in arresting  my- 
oblast  fusion  (39).  As  shown  in  Fig.  4B,  EGTA-arrested 
myoblasts display a characteristic  elongated bipolar shape (see 
also reference 39), which is distinct from the morphology of 
prefusional myoblasts (Fig.  4A) or fusion-arrested myoblasts 
obtained  by  various  other means,  such  as  treatment  with 
bromodeoxyuridine, cycloheximide (18), a prostaglandin an- 
tagonist (7), and an inhibitor of protein glycosylation (34). As 
shown in Fig.  4, B  and C, the appearance of cells inhibited 
from fusing by TFP is verY similar to that of EGTA-arrested 
myoblasts. Myoblasts that are fusion-blocked with W-5, W-7, 
or CPZ  closely resemble  the TFP-arrested  cells  (results not 
shown).  Untreated  cultures of the same  age  are  fully fused 
(Fig. 40). 
A  characteristic  aspect  of  muscle  differentiation  is  the 
expression of AChR on the cell surface (19). As shown in Fig. 
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5, the block of fusion induced by TFP does not impair the 
appearance of AChR. In both TFP-blocked and control cul- 
tures, the amounts of surface AChR increase sharply at similar 
rates during the second day in culture.  In this respect,  TFP 
treatment resembles Ca  2÷ depletion by EGTA (Fig.  5) or by 
replacement of growth medium with Ca2÷-free medium (38), 
FiGure  4  Effects  of TFP and EGTA on myoblast fusion. (A) Prefu- 
sional  myoblasts  at 24 h postplating.-(B)  EGTA-treated  cultures 54 
h postplating; EGTA (1.8  raM) was added  at 24  h  postplating.  (C) 
TFP-treated  cultures 54  h postplating; TFP (7.5 #M) was added  at 
24 h postplating.  (D) Control cultures at 54 h postplating. Cultures 
were fixed and stained as described under Materials and Methods. 
Note the morphological similarity between EGTA treated cells and 
TFP-treated  cells, and the distinct morphology displayed by prefu- 
sional myoblasts.  Bar, 50/Lm.  x  350. 
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FIGURE  5  Appearance  of 
surface  AChR  in  control 
cultures (I), EGTA-treated 
cultures  (11),  and  TFP- 
treated cultures (A).  EGTA 
(1.8 mM) and TFP (10 pM) 
were added  to cultures at 
24  h  postplating.  Surface 
AChR  was  measured  by 
the specific binding of 12Sl- 
Bgt  as  described  under 
Materials  and  Methods. 
Amount of protein per cul- 
ture dish  was  determined 
in replicate cultures.  Data 
points  represent  averages 
of  triplicate  measure- 
ments. 
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expression of surface AChR. 
To test whether a  rise in intracellular Ca  2÷ will affect the 
TFP-induced inhibition of muscle fusion, we used the Ca  2+ 
ionophore A23187, which has been shown to increase mem- 
brane permeability for this cation (46). Myoblasts were treated 
with the ionophore (0.5 uM) at 25 h postplating, 1 h after the 
addition  of TFP.  As  shown  in  Fig.  6A,  the  inhibition  of 
myoblast fusion  caused by treatment with  10  uM  TFP is 
clearly attenuated in the presence of A23187. The reversal by 
the Ca  2÷ ionophore is incomplete, allowing fusion to reach 
levels comparable to those observed in cells treated with  5 
uM TFP. In comparison, the ionophore has no effect on the 
inhibition of muscle fusion by 5 uM TFP. As can be seen in 
Fig.  6,  B-D,  the  inhibition  of fusion  by  10  #M  TFP  is 
characterized by reduced alignment of myoblasts (Fig. 6 C), 
as compared with the inhibition obtained with  5  uM  TFP 
(Fig. 6B). In the presence of the ionophore, cultures treated 
FIGURE  6  Effect  of the Ca  2+ ionophore A23187 on the inhibition 
of muscle fusion by TFP. (A) Cultures were treated with TFP at 24 
h postplating and A23187 (0.5/~M) was added after l-h exposure 
to TFP. Percentage fusion  in control and TFP-treated cultures,  in 
the presence or absence of A23187 was determined 30 h after the 
addition of TFP. Values shown are the averages of four determina- 
tions. Bars represent the range. (B-D) Effect of TFP and A23187 on 
myoblast alignment. Cultures were treated with TFP and A23187 as 
described  above.  Note  the  nonimpaired myoblast alignment  in 
cultures  treated  with  5  /~M  TFP  (B), the  reduced  alignment  in 
cultures treated with 10 ~M TFP (C), and the restored alignment in 
cultures treated with  10 ~M TFP and A23187 (D).  Bars, 50 ~m.  × 
350. 
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with 10 uM TFP display enhanced alignment (Fig. 6D) similar 
to that observed in cultures treated with 5 uM TFP (Fig. 6B). 
To establish the presence and distribution of calmodulin, 
we used immunofluoreseence microscopy, using anticalmo- 
dulin antibody. The immunofluoreseent staining pattern of 
calmodulin in prefusional myoblasts (24 h postplating), fusing 
myoblasts, and fused myotubes is shown in Fig. 7. Appreciable 
staining of muscle cells is observed at all stages of develop- 
ment. Prefusional myoblasts display a diffuse staining pattern, 
with a  somewhat higher intensity in perinuclear regions.  In 
addition, a  proportion of these myoblasts exhibits localized 
regions of intense  staining  at  the cell tips  (Fig.  7A,  lower 
panel).  This staining  pattern  appears to  be transient,  and 
shortly after  onset  of fusion,  a  uniform  staining  is  again 
observed (Fig. 7 B). The pattern of calmodulin staining is not 
affected by TFP treatment (results not shown). 
DISCUSSION 
In the present study we have investigated the effects on muscle 
fusion  of several  pharmacological agents known  to inhibit 
calmodulin. We have found that the phenothiazines TFP and 
CPZ, as well as the sulfonamide derivatives W-5 and W-7, 
inhibit myoblast fusion at doses that correspond closely to 
the doses reported to inhibit the activity of Ca2+-calmodulin 
in vitro (13,  14, 50). 
TFP and other phenothiazines are known to have hydro- 
phobic properties (47) that may result in membrane-perturb- 
ing effects (41,  43,  44).  Several considerations argue against 
the possibility that the inhibitory effects of TFP on muscle 
fusion result from its membrane-perturbing properties. First, 
we observed that the phenothiazine CPZ, although it possesses 
hydrophobic properties similar to those of TFP, is less effec- 
tive than TFP in blocking myoblast fusion. Second, we found 
that two other calmodulin inhibitors, W-5 and W-7,  which 
are structurally unrelated to phenothiazines, inhibit myoblast 
fusion. Third, our observation that elevation of intracellular 
Ca  2÷ concentration by the Ca  2÷ ionophore A23187 diminishes 
the TFP-induced fusion block is consistent with an intracel- 
lular site of action for TFP. 
The essential role of Ca  2÷ in  mediating muscle fusion is 
well documented (8,  38,  39,  48, 49).  Several aspects of the 
TFP-induced inhibition of muscle fusion support the possi- 
bility that TFP interferes with Ca2+-dependent  mechanisms 
regulating fusion. TFP-arrested myoblasts display a  unique 
bipolar elongated  morphology which  is  similar  to  that  of 
myoblasts prevented from fusing by Ca  2÷ deprivation (Fig. 4; 
see also reference 39). Furthermore, as in the case of EGTA- 
arrested myoblasts, the fusion block by TFP does not impair 
the elaboration of surface AChR. In addition, the inhibitory 
effect of TFP can be partially overcome in the presence of the 
Ca  2÷ ionophore A23187. This observation is consistent with 
the possibility that the TFP-induced block of muscle fusion 
is associated with impaired availability of cellular Ca  2÷. This 
interpretation is supported by a previous finding which sug- 
gested that  an  increase in  intracellular Ca  2÷ constituted an 
essential step in myoblast fusion (8). Furthermore, TFP has 
been shown to inhibit Ca  2÷ transport processes in erythrocytes 
(15,  25,  45) and  lymphocytes (26).  The ability of the Ca  2÷ 
ionophore to reverse the inhibition by TFP of Ca2+-mediated 
processes has been reported previously (11 ). 
It is noteworthy that the ionophore is effective in reversing 
the fusion block only to ~60% of the control levels. Conse- FIGURE  7  Immunofluorescence staining of calmodulin in muscle  cells.  (a)  Prefusional  myoblasts  24  h  postplating.  Note  the 
elevated staining at the tip of the prefusional myoblast shown in the lower panel.  (b) Myoblasts 28 h postplating, shortly after 
onset of fusion. (c) Fused myotubes 96 h postplating. Cultures used for staining of fused  myotubes were treated  with cytosine 
arabinoside (10/~M) at 48 h postplating for 2 d to minimize fibroblast proliferation. Fixation and staining procedures are described 
under Materials and Methods. Bar, 20/~m.  X 725. 
quently, the reversal of the fusion block is apparent only at 
maximal levels of fusion inhibition obtained with 10 uM TFP 
and is not detected under conditions of partial fusion block 
induced by 5  ~M  TFP (Fig.  6).  Several studies have noted 
that fusion of cultured myoblasts is preceded by alignment of 
mononucleated cells (8, 2 l, 22,  32). Various procedures that 
cause fusion-arrest result in impaired alignment (16,  39, 48), 
whereas others do not (1,  16, 32), which indicates that myo- 
blast  alignment  and  fusion  constitute  distinct  steps  in  the 
formation of multinucleated  myotubes. Of relevance is our 
observation that the alignment of fusion-blocked myoblasts 
is impaired at the higher TFP concentration used, but appears 
to be unaffected at lower concentrations of the phenothiazine. 
Moreover, the impairment of myoblast alignment by l0 ~tM 
TFP is to a large extent prevented in the presence of the Ca  2+ 
ionophore.  These results indicate  that  a  component of the 
TFP block is associated with the Ca  2+ requirement of myo- 
blast alignment.  This component can  be overcome by the 
Ca  2+  ionophore,  and  presumably reflects  an  inhibition  by 
TFP of a  Ca  2+ entry mechanism. An additional component 
of the TFP block cannot be overcome by the ionophore and 
is apparently associated with  the  interference of TFP with 
subsequent  steps,  independent  of Ca  2÷  entry,  that  mediate 
muscle fusion. 
The phenothiazine TFP has been shown to bind tightly to 
purified Ca2÷-calmodulin (23,  24) and to inhibit calmodulin 
activity by preventing its interaction with receptor enzymes 
(2, 25, 51). Recently, TFP and other phenothiazines have also 
been  shown  to  interact with  Ca2÷-binding proteins distinct 
from calmodulin  (4,  30,  31).  We  have  found  that  muscle 
fusion is inhibited by the phenothiazines TFP and CPZ, as 
well as  by W-7  and  W-5,  calmodulin  antagonists  that  are 
structurally unrelated to the phenothiazines.  These findings 
are consistent with the possibility that TFP exerts its inhibitory 
effect on  myoblast fusion by interfering with either calmo- 
dulin or pharmacologically closely related Ca2+-binding  pro- 
tein(s).  The capacity of the  various pharmacological agents 
used in this study to inhibit myoblast fusion, at doses that in 
each case closely correspond to their antagonistic effect on 
calmodulin activity in vitro, further suggests that the inhibi- 
tion  of muscle  fusion  results  primarily from inhibition  of 
Ca2÷-calmodulin. 
What role may calmodulin play in the regulation of muscle 
fusion? Calmodulin has been shown to activate at least two 
processes responsible for controlling intracellular concentra- 
tions of Ca2÷: the Ca  2÷ pumps of the plasma membrane and 
the sarcoplasmic reticulum (for review see reference 20). The 
sensitivity of the  fusion  process to  TFP and  the  ability to 
partially overcome the inhibitory effect of TFP by increasing 
Ca  2÷ entry to cells may reflect the participation of calmodulin 
in the regulation of Ca  2+ transport mechanisms required for 
fusion.  Based on  our observations that the  reversal of TFP 
fusion block by ionophore-induced Ca  2+ entry is incomplete, 
it appears likely that the transduction of the Ca  ~÷ requirement 
for muscle fusion involves an additional calmodulin-mediated 
regulatory mechanism. 
Ultrastructural studies of muscle fusion have indicated that 
the formation of  particle-depleted plasma membrane domains 
is an essential  step in  myoblast fusion (19).  In view of the 
increasing evidence for the role ofcytoskeleton in modulating 
cell-surface organization (40),  the  changes in  plasma mem- 
brane properties that accompany fusion may be regulated by 
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that  localized  changes  in  the  organization  of cytoskeletal 
components subjacent to the plasma membrane at the fusing 
tips  of myoblasts  are  relevant  (10).  The  potential  role  of 
calmodulin in regulating cytoskeletal organization is suggested 
by the observations that calmodulin mediates the calcium- 
dependent  assembly-disassembly  of microtubules  (28)  and 
that this protein activates a specific myosin light-chain kinase, 
which in turn regulates the activity of the myosin associated 
with microfilaments (6). Therefore, the participation of cal- 
modulin in the process of muscle fusion may involve changes 
in cytoskeletal organization, which in turn alter surface mem- 
brane properties.  The elevated staining of calmodulin at the 
tips of fusion-competent myoblasts, observed in the present 
study, appears to be spatially correlated with areas of special- 
ized cytoskeletal organization observed previously (10). More- 
over, the expression of both properties is transient and occurs 
at the onset of muscle fusion. This correlation is consistent 
with the possibility that calmodulin may play a  role in the 
production of localized changes in cell-surface  organization 
compatible with myoblast fusion. 
The fusion of mononucleated myoblasts to form multinu- 
cleated myotubes is a striking aspect of muscle differentiation. 
Numerous studies have shown fusion of muscle cells to be a 
multistep process involving a variety of coordinated changes 
in cell-surface  structural and functional properties (12, 16, 18, 
19, 42). The requirement for Ca  2÷ of the process of muscle 
fusion has been known for more than a decade. However, the 
mechanisms by which Ca  2÷ exerts its essential role in fusion 
are as yet unknown. In view of the increasing evidence for 
the  role  of  calmodulin  in  various  Ca2+-mediated  cellular 
processes,  the susceptibility of muscle fusion to calmodulin 
antagonists focuses attention on the possibility that this Ca  2÷- 
binding protein may participate in the regulation of muscle 
fusion. 
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